Sanofi/AstraZeneca’s Nirsevimab Is Set To Transform RSV Treatment In Infants

 
• By Brenda Sandburg
RSV infants
The biologics license application for the first RSV prophylaxis for all infants is under FDA review. • Source: Shutterstock

More from Interviews

More from Pink Sheet